Protocol Ledger

NCT05405868 · Phase III · RECRUITING

Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial

Interventional Phase III clinical trial protocol NCT05405868 sponsored by University College, London in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-18 Enrollment: 496 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05405868
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)496 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05405868
Protocol FieldVerified Registry Value
NCT IdentifierNCT05405868
Consolidated Lead SponsorUniversity College, London
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment496 participants (ESTIMATED)
Registered Start Date2024-01-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05405868
Hospital Research SiteLocationSite Profile
King's College Hospital NHS Foundation TrustLondon, United KingdomOpen Hospital Dossier ->
Nottingham University Hospitals NHS TrustNottingham, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI